author-photo

Doris Quon

University of California, Los Angeles

68

Papers

822

Citations

Citation Trend

Filter By

Papers (45) Sort By

Journal Conference Others

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.

2021 Haemophilia
Show All
- Source
- Cite
- Save
Citations (0)
A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors

2021 Haemophilia
Show All
- Source
- Cite
- Save
Citations (1)
Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE)

2021 Journal of Blood Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efanesoctocog Alfa Half-Life and Clearance Are Independent of von Willebrand Factor in Severe Hemophilia A: A Post Hoc Analysis from Phase 1/2a Studies

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

2020 Blood
Show All
- Source
- Cite
- Save
Citations (4)
SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A

2020 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (17)